24
Participants
Start Date
March 7, 2023
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2026
Radiprodil
Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
ERASMUS Medisch Centrum, Developmental & Genetic pediatrics, Rotterdam
UMC Utrecht - Wilhelmina Kinderziekenhuis, Polikliniek Kinderneurologie, Utrecht
Queensland Children's Hospital, South Brisbane
Columbia University Irving Medical Center, Dept of Neurology, New York
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
Hospital Ruber Internacional, Madrid
Azienda Ospedaliero Universitaria Careggi (AOUC) Firenze - Azienda Ospedaliera Universitaria Meyer, Florence
KBO-Kinderzentrum München gemeinnützige GmbH, München
The Hospital for Sick Children (Sick Kids), Toronto
BC Children's Hospital, Vancouver
Abteilung für Neuropädiatrie, Klinik und Poliklinik für Kinder - und Jugendmedizin, Universitätsklinikum Leipzig, Leipzig
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Pediatrico Bambino Gesu, Rome
Universitat de Barcelona - Hospital Sant Joan de Deu Barcelona (HSJDB), Barcelona
Royal Hospital for Children Glasgow, Glasgow
Great Ormond Street Hospital For Children NHS Foundation Trust, London
Lead Sponsor
GRIN Therapeutics, Inc.
INDUSTRY